0 results for 'Sanofi SA'
Icahn Blasts ImClone Management
In the wake of a judge's ruling that stripped ImClone Systems of key exclusive patent rights, the biotech's biggest rival wasted little time taking advantage of the situation. After the market closed Tuesday, biotech giant Amgen Inc. said it had licensed the same technology to which ImClone lost its exclusive rights. Meanwhile, in what could lead to a full-blown power struggle, newly elected ImClone director Carl Icahn blasted management for the patent loss and for ImClone's "sorry record" in general.FDA Appointee, Senator Clash Over Disclosure on Antibiotic
President Bush's choice to head the FDA is refusing to give Congress all the information it seeks about the controversial antibiotic Ketek, setting up further confrontations with Sen. Charles Grassley, R-Ia., who is blocking his nomination. The acting FDA chief says full disclosure of the information about Ketek could have a chilling effect on the agency's ability to be an independent evaluator of drug safety issues. Ketek has been linked to severe liver problems and several deaths.High Court Turns Down Amgen's Appeal in Patent Case
The Supreme Court on Monday declined to consider a patent dispute between biotech drug maker Amgen Inc. and two other companies involving Amgen's blockbuster anemia drug Epogen. Amgen urged the justices to rule on the Federal Circuit's practice of considering the factual record behind its patent claims, stating in its filing that the practice "produces incorrect results and causes litigants and district courts to waste tremendous resources."Panel finds vaccines with mercury didn't cause autism
Families whose children developed autism after taking a vaccine that contained mercury aren't entitled to compensation from the U.S. government, a panel of court-appointed experts ruled. Three "special masters" appointed by the U.S. Court of Federal Claims in Washington found today that the families failed to show vaccines with thimerosal, a preservative containing mercury, could contribute to autism or gastrointestinal dysfunction.High Court Turns Down Amgen's Appeal in Patent Case
The Supreme Court on Monday declined to consider a patent dispute between biotech drug maker Amgen Inc. and two other companies involving Amgen's blockbuster anemia drug Epogen. Amgen urged the justices to rule on the Federal Circuit's practice of considering the factual record behind its patent claims, stating in its filing that the practice "produces incorrect results and causes litigants and district courts to waste tremendous resources."High court turns down Amgen's appeal in patent case
The Supreme Court on Monday declined to consider a patent dispute between biotech drug maker Amgen Inc. and two other companies involving Amgen's blockbuster anemia drug Epogen. Amgen urged the justices to rule on the Federal Circuit's practice of considering the factual record behind its patent claims, stating in its filing that the practice "produces incorrect results and causes litigants and district courts to waste tremendous resources."Corporate Transparency Act Resource Kit
Brought to you by Wolters Kluwer
Download Now
Revenue, Profit, Cash: Managing Law Firms for Success
Brought to you by Juris Ledger
Download Now
Law Firm Operational Considerations for the Corporate Transparency Act
Brought to you by Wolters Kluwer
Download Now
The Ultimate Guide to Remote Legal Work
Brought to you by Filevine
Download Now